IDEAYA BIOSCIENCES INC (IDYA) Fundamental Analysis & Valuation

NASDAQ:IDYA • US45166A1025

Current stock price

33.32 USD
+1.87 (+5.95%)
At close:
33.32 USD
0 (0%)
Pre-Market:

This IDYA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. IDYA Profitability Analysis

1.1 Basic Checks

  • In the past year IDYA has reported negative net income.
  • IDYA had a negative operating cash flow in the past year.
  • IDYA had negative earnings in each of the past 5 years.
  • In the past 5 years IDYA always reported negative operating cash flow.
IDYA Yearly Net Income VS EBIT VS OCF VS FCFIDYA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M

1.2 Ratios

  • The Return On Assets of IDYA (-10.21%) is better than 82.79% of its industry peers.
  • Looking at the Return On Equity, with a value of -11.07%, IDYA belongs to the top of the industry, outperforming 85.88% of the companies in the same industry.
Industry RankSector Rank
ROA -10.21%
ROE -11.07%
ROIC N/A
ROA(3y)-17.35%
ROA(5y)-16.05%
ROE(3y)-18.41%
ROE(5y)-17.7%
ROIC(3y)N/A
ROIC(5y)N/A
IDYA Yearly ROA, ROE, ROICIDYA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for IDYA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IDYA Yearly Profit, Operating, Gross MarginsIDYA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. IDYA Health Analysis

2.1 Basic Checks

  • IDYA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IDYA has more shares outstanding than it did 1 year ago.
  • IDYA has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IDYA Yearly Shares OutstandingIDYA Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
IDYA Yearly Total Debt VS Total AssetsIDYA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • IDYA has an Altman-Z score of 19.77. This indicates that IDYA is financially healthy and has little risk of bankruptcy at the moment.
  • IDYA has a Altman-Z score of 19.77. This is amongst the best in the industry. IDYA outperforms 88.78% of its industry peers.
  • There is no outstanding debt for IDYA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 19.77
ROIC/WACCN/A
WACC9.29%
IDYA Yearly LT Debt VS Equity VS FCFIDYA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M 800M 1B

2.3 Liquidity

  • IDYA has a Current Ratio of 11.34. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
  • IDYA has a Current ratio of 11.34. This is amongst the best in the industry. IDYA outperforms 83.75% of its industry peers.
  • IDYA has a Quick Ratio of 11.34. This indicates that IDYA is financially healthy and has no problem in meeting its short term obligations.
  • IDYA has a Quick ratio of 11.34. This is amongst the best in the industry. IDYA outperforms 83.95% of its industry peers.
Industry RankSector Rank
Current Ratio 11.34
Quick Ratio 11.34
IDYA Yearly Current Assets VS Current LiabilitesIDYA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. IDYA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 60.30% over the past year.
  • Looking at the last year, IDYA shows a very strong growth in Revenue. The Revenue has grown by 3024.43%.
  • Measured over the past years, IDYA shows a very strong growth in Revenue. The Revenue has been growing by 62.10% on average per year.
EPS 1Y (TTM)60.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.91%
Revenue 1Y (TTM)3024.43%
Revenue growth 3Y62.54%
Revenue growth 5Y62.1%
Sales Q2Q%55.37%

3.2 Future

  • IDYA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.74% yearly.
  • The Revenue is expected to grow by 36.22% on average over the next years. This is a very strong growth
EPS Next Y-203.57%
EPS Next 2Y-67.33%
EPS Next 3Y-34.08%
EPS Next 5Y28.74%
Revenue Next Year-79.2%
Revenue Next 2Y-22.19%
Revenue Next 3Y3.26%
Revenue Next 5Y36.22%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IDYA Yearly Revenue VS EstimatesIDYA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
IDYA Yearly EPS VS EstimatesIDYA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

0

4. IDYA Valuation Analysis

4.1 Price/Earnings Ratio

  • IDYA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IDYA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IDYA Price Earnings VS Forward Price EarningsIDYA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IDYA Per share dataIDYA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • A cheap valuation may be justified as IDYA's earnings are expected to decrease with -34.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-67.33%
EPS Next 3Y-34.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IDYA Dividend Analysis

5.1 Amount

  • IDYA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IDYA Fundamentals: All Metrics, Ratios and Statistics

IDEAYA BIOSCIENCES INC

NASDAQ:IDYA (3/31/2026, 8:00:01 PM)

Premarket: 33.32 0 (0%)

33.32

+1.87 (+5.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-04
Inst Owners112.19%
Inst Owner Change1.32%
Ins Owners0.91%
Ins Owner Change1.14%
Market Cap2.93B
Revenue(TTM)218.71M
Net Income(TTM)-113.21M
Analysts84.8
Price Target49.98 (50%)
Short Float %11.36%
Short Ratio10.92
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)172.05%
Min EPS beat(2)4.76%
Max EPS beat(2)339.34%
EPS beat(4)2
Avg EPS beat(4)78.31%
Min EPS beat(4)-21.53%
Max EPS beat(4)339.34%
EPS beat(8)3
Avg EPS beat(8)20.84%
EPS beat(12)6
Avg EPS beat(12)15.91%
EPS beat(16)9
Avg EPS beat(16)19.73%
Revenue beat(2)2
Avg Revenue beat(2)2014.66%
Min Revenue beat(2)70.85%
Max Revenue beat(2)3958.47%
Revenue beat(4)2
Avg Revenue beat(4)957.33%
Min Revenue beat(4)-100%
Max Revenue beat(4)3958.47%
Revenue beat(8)3
Avg Revenue beat(8)447.05%
Revenue beat(12)5
Avg Revenue beat(12)293.25%
Revenue beat(16)7
Avg Revenue beat(16)247.71%
PT rev (1m)-3.48%
PT rev (3m)-1.26%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)-3.35%
EPS NY rev (1m)-8.63%
EPS NY rev (3m)-10.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-19.19%
Revenue NY rev (1m)-22.92%
Revenue NY rev (3m)-22.22%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.38
P/FCF N/A
P/OCF N/A
P/B 2.86
P/tB 2.86
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-3.98
Fwd EYN/A
FCF(TTM)-0.84
FCFYN/A
OCF(TTM)-0.81
OCFYN/A
SpS2.49
BVpS11.65
TBVpS11.65
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.21%
ROE -11.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-17.35%
ROA(5y)-16.05%
ROE(3y)-18.41%
ROE(5y)-17.7%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 87.7%
Cap/Sales 1.08%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 11.34
Quick Ratio 11.34
Altman-Z 19.77
F-Score5
WACC9.29%
ROIC/WACCN/A
Cap/Depr(3y)114.98%
Cap/Depr(5y)132.27%
Cap/Sales(3y)22.1%
Cap/Sales(5y)16.5%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.91%
EPS Next Y-203.57%
EPS Next 2Y-67.33%
EPS Next 3Y-34.08%
EPS Next 5Y28.74%
Revenue 1Y (TTM)3024.43%
Revenue growth 3Y62.54%
Revenue growth 5Y62.1%
Sales Q2Q%55.37%
Revenue Next Year-79.2%
Revenue Next 2Y-22.19%
Revenue Next 3Y3.26%
Revenue Next 5Y36.22%
EBIT growth 1Y51.23%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-129.79%
EBIT Next 3Y-9.17%
EBIT Next 5YN/A
FCF growth 1Y70.78%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y71.28%
OCF growth 3YN/A
OCF growth 5YN/A

IDEAYA BIOSCIENCES INC / IDYA Fundamental Analysis FAQ

What is the fundamental rating for IDYA stock?

ChartMill assigns a fundamental rating of 4 / 10 to IDYA.


Can you provide the valuation status for IDEAYA BIOSCIENCES INC?

ChartMill assigns a valuation rating of 0 / 10 to IDEAYA BIOSCIENCES INC (IDYA). This can be considered as Overvalued.


What is the profitability of IDYA stock?

IDEAYA BIOSCIENCES INC (IDYA) has a profitability rating of 2 / 10.


What is the financial health of IDEAYA BIOSCIENCES INC (IDYA) stock?

The financial health rating of IDEAYA BIOSCIENCES INC (IDYA) is 8 / 10.